Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Spinal cord injury
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Preclinical/no trial
- ChEMBL max phase
- 2 / 4 (development scale, not regulatory approval)
- Synonyms
- Estradiol 3-benzoate; Estradiol benzoate; Benztrone; Progynon B oleoso; NSC-9566
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatSpinal cord injuryContusionSprague-DawleyFemale (ovariectomised)n = At least five treatment groups; n=10 per group for estradio…Subcutaneous implant or pellet placed in the midscapular region3 mg estradiol benzoate in a 5 mm silastic implant; 15 mg t…Implanted immediately after ovariectomy, 7 days before spinal cord injury
Model: Moderate T9-T10 contusion spinal cord injury using the NYU impactor, 10 g rod 2.5 mm diameter dropped from 12.5 mm
Estradiol raised mean plasma levels to about 154 pg/mL at injury and improved BBB scores at 7, 14, 21 and 28 days post-injury (for example 14.6 versus 11.8 at 28 days), reduced lesion area and increased spared tissue, effects blocked by the estrogen receptor alpha antagonist MPP. Estradiol reduced…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.